AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9682649 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-layer bandage (FLB)
Number of subjects: 53
Study 9682649 — intervention group
Group type: COMPARATOR
Intervention: Short stretch bandage (SSB)
Number of subjects: 53
Study 9682649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FLB and SSB
Number of subjects: 53
Study 7592505 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 3770
Number of subjects: 150
Study 7592505 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 150
Study 7592505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 2312775 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/ZOK 100 mg once daily
Number of subjects: 18
Study 2312775 — intervention group
Group type: COMPARATOR
Intervention: Conventional Metoprolol Tablets (CT) 100 mg once daily
Number of subjects: 18
Study 2312775 — intervention group
Group type: COMPARATOR
Intervention: Conventional Metoprolol Tablets (CT)
Number of subjects: 18
Study 497315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 497315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 6
Study 497315 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 6
Study 497315 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 6
Study 30982808 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based health counselling in intervention group
Number of subjects: 15710
Study 30982808 — intervention group
Group type: COMPARATOR
Intervention: Usual care standard counselling in usual care group
Number of subjects: 15710
Study 31618382 — intervention group
Group type: EXPERIMENTAL
Intervention: PRENACEL program (communication program via short cellphone text messages)
Number of subjects: 1210
Study 31618382 — intervention group
Group type: EXPERIMENTAL
Intervention: PRENACEL program
Number of subjects: 1210
Study 31618382 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1210
Study 27539149 — intervention group
Group type: EXPERIMENTAL
Intervention: SLActive implants
Number of subjects: 20
Study 27539149 — intervention group
Group type: COMPARATOR
Intervention: SLA implants
Number of subjects: 20
Study 26288392 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice (10 mL/(kg·min) for 28 days)
Number of subjects: 28
Study 26288392 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (isocaloric, isoglycemic, isovolumetric)
Number of subjects: 28
Study 23220158 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise (HIIE) program three times per week for 12 weeks
Number of subjects: 34
Study 23220158 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise (HIIE)
Number of subjects: 34
Study 21702687 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved diclofenac sodium 0.1% (Voltaren Ophtha)
Number of subjects: 30
Study 21702687 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free diclofenac (Dicloftil)
Number of subjects: 30
Study 17999159 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (8 mg)
Number of subjects: 62
Study 17999159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg)
Number of subjects: 62
Study 17999159 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 62
Study 17072691 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 microg sufentanil
Number of subjects: 100
Study 17072691 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microg sufentanil
Number of subjects: 100
Study 17072691 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 microg sufentanil
Number of subjects: 100
Study 17072691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no sufentanil)
Number of subjects: 100
Study 12930432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine (twice daily for 16 weeks)
Number of subjects: 1380
Study 10718389 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80
Study 10718389 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 80
Study 1680813 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lisinopril
Number of subjects: 32
Study 1680813 — intervention group
Group type: COMPARATOR
Intervention: 100 mg atenolol
Number of subjects: 32
Study 1680813 — intervention group
Group type: COMPARATOR
Intervention: 20 mg nitrendipine
Number of subjects: 32
Study 1680813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7039760 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosaramicin 250 mg six hourly for seven days
Number of subjects: 94
Study 7039760 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline 250 mg six hourly for seven days
Number of subjects: 94
Study 31456562 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (7 sessions)
Number of subjects: 615
Study 31456562 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (7 sessions)
Number of subjects: 615
Study 31456562 — intervention group
Group type: COMPARATOR
Intervention: Single session of physiotherapy (SSPT)
Number of subjects: 615
Study 29422473 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics at the time of admission
Number of subjects: 50
Study 29422473 — intervention group
Group type: COMPARATOR
Intervention: Perioperative antibiotics at the time of induction of general anesthesia
Number of subjects: 50
Study 27247220 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin/paclitaxel followed by neoadjuvant radiochemotherapy (RCT) to 45 Gy (1.5 Gy twice per day concurrent cisplatin/vinorelbine)
Number of subjects: 161
Study 25194768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day manipulation
Number of subjects: 43
Study 25194768 — intervention group
Group type: COMPARATOR
Intervention: 7-day manipulation
Number of subjects: 43
Study 22963812 — intervention group
Group type: EXPERIMENTAL
Intervention: NCX 4016 (800 mg, twice daily)
Number of subjects: 442
Study 22963812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 20372668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutoring peers in oral health (Part 2)
Number of subjects: 49
Study 20372668 — intervention group
Group type: COMPARATOR
Intervention: Adult toothbrushing technique (modified Bass technique) (Part 1)
Number of subjects: 49
Study 18357917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine therapy using colony-stimulating factors (CSF) for bone marrow mobilisation
Number of subjects: 0
Study 18357917 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injection of monocyte chemoattractant protein 1 (MCP-1)
Number of subjects: 0
Study 18357917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bone marrow mobilisation and MCP-1 injection
Number of subjects: 0
Study 16192416 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 0
Study 16192416 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 16192416 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amiloride and spironolactone
Number of subjects: 0
Study 16192416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12038846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraporous beta-tricalcium phosphate (beta-TCP) combined with allograft and venous blood as an extender
Number of subjects: 7
Study 10333091 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (100 mg coenzyme Q10, 600 mg ascorbic acid, 270 mg alpha-tocopherol)
Number of subjects: 7
Study 10333091 — intervention group
Group type: COMPARATOR
Intervention: Control phase (placebo)
Number of subjects: 7
Study 10333091 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant phase
Number of subjects: 7
Study 10333091 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 7
Study 10333091 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 31P‐NMRS/low frequency fatigue test
Number of subjects: 7
Study 10333091 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle fatigue at 10 Hz electrical stimulation
Number of subjects: 7
Study 8613560 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine
Number of subjects: 15
Study 8613560 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil/phenolic rinse
Number of subjects: 15
Study 8613560 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-adhesive/chlorhexidine rinse
Number of subjects: 15
Study 8613560 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-adhesive rinse
Number of subjects: 15
Study 8613560 — intervention group
Group type: COMPARATOR
Intervention: Water rinse
Number of subjects: 15
Study 2268915 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng‐Rhizome saponin (GRS) 50 mg per tablet, three times a day for two months
Number of subjects: 358
Study 2268915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 358
Study 6856487 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 0
Study 6856487 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 1,000 mg
Number of subjects: 0
Study 6856487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6856487 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 0
Study 6856487 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 600 mg
Number of subjects: 0
Study 6856487 — intervention group
Group type: COMPARATOR
Intervention: Propoxyphene napsylate 100 mg
Number of subjects: 0
Study 6856487 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen with codeine 60 mg
Number of subjects: 0
Study 6856487 — intervention group
Group type: COMPARATOR
Intervention: Propoxyphene with 100 mg
Number of subjects: 0
Study 30664702 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic group (n=194)
Number of subjects: 1213
Study 30664702 — intervention group
Group type: COMPARATOR
Intervention: Nonanemic group (n=1019)
Number of subjects: 1213
Study 30664702 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall hypertensive patients with well-controlled blood pressure
Number of subjects: 1213
Study 29957314 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect bonding (group B)
Number of subjects: 30
Study 29957314 — intervention group
Group type: COMPARATOR
Intervention: Direct bonding (group A)
Number of subjects: 30
Study 26955675 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous tantalum rod combined with Gugutou Huaisiyu Capsule (GHC)
Number of subjects: 50
Study 26955675 — intervention group
Group type: COMPARATOR
Intervention: Porous tantalum rod
Number of subjects: 50
Study 26955675 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous tantalum rod combined with GHC
Number of subjects: 50
Study 24566538 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascularized bone grafting (VBG) using the 1, 2 intercompartmental suprareticular artery
Number of subjects: 75
Study 24566538 — intervention group
Group type: COMPARATOR
Intervention: Distal radius nonvascularized bone graft
Number of subjects: 75
Study 22953794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac shock wave therapy (CSWT)
Number of subjects: 21
Study 22953794 — intervention group
Group type: COMPARATOR
Intervention: Placebo (acoustic simulation without energy application)
Number of subjects: 21
Study 20308663 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of docetaxel, bevacizumab, thalidomide, and prednisone
Number of subjects: 60
Study 17965284 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 15
Study 16150065 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention delivered by GPs focusing on nutrition, physical activity, and sedentary behaviour over 12 weeks in four consultations
Number of subjects: 163
Study 16150065 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (GPs) trained in management of childhood overweight
Number of subjects: 163
Study 16150065 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI survey conducted by practice staff
Number of subjects: 163
Study 16150065 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment of families for the LEAP RCT
Number of subjects: 163
Study 12975277 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive tracer (10 mCi of technetium 99m‐labeled macroaggregated albumin in 10 mL of physiologic saline)
Number of subjects: 25
Study 12975277 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 25
Study 10536315 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 30 mg
Number of subjects: 40
Study 10536315 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 40
Study 10536315 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 40
Study 10536315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9084524 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 2 mg/kg
Number of subjects: 80
Study 9084524 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms/kg
Number of subjects: 80
Study 9084524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg
Number of subjects: 80
Study 9084524 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 80
Study 1745620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g every 12 hours plus metronidazole 500 mg every 6 hours intravenously
Number of subjects: 35
Study 1745620 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 1.5 mg/kg plus clindamycin 900 mg every 8 hours intravenously
Number of subjects: 35
Study 17152739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergotamine 1 mg
Number of subjects: 24
Study 17152739 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 24
Study 17152739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergotamine 1 mg + Metoclopramide 20 mg
Number of subjects: 24
Study 17152739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergotamine 2 mg + Metoclopramide 20 mg
Number of subjects: 24
Study 30663456 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular micro-bypass stents (TBS)
Number of subjects: 0
Study 30663456 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 27927009 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardcel
Number of subjects: 32
Study 27927009 — intervention group
Group type: COMPARATOR
Intervention: Merocel
Number of subjects: 32
Study 27116364 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment group (two, 150-minute group sessions spaced one-week apart)
Number of subjects: 32
Study 27116364 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 32
Study 23520350 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery
Number of subjects: 65
Study 23520350 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 65
Study 22145698 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 561
Study 22145698 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 10 mg
Number of subjects: 561
Study 22145698 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 561
Study 22145698 — intervention group
Group type: COMPARATOR
Intervention: voglibose
Number of subjects: 561
Study 22145698 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg, linagliptin 10 mg, placebo, voglibose
Number of subjects: 561
Study 19280566 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function training for 3 years
Number of subjects: 25
Study 19280566 — intervention group
Group type: COMPARATOR
Intervention: No executive function training (control group)
Number of subjects: 25
Study 17719682 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free valve connection system (NFVCS)
Number of subjects: 799
Study 17719682 — intervention group
Group type: COMPARATOR
Intervention: Three-way stopcock connection (3WSC)
Number of subjects: 799
Study 14715975 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (tPA)
Number of subjects: 615
Study 11216952 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) on a bicycle ergometer for four weeks (n = 11)
Number of subjects: 22
Study 11216952 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (n = 11)
Number of subjects: 22
Study 11216952 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) on a bicycle ergometer
Number of subjects: 22
Study 9648963 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline
Number of subjects: 14
Study 9648963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7865532 — intervention group
Group type: EXPERIMENTAL
Intervention: Obliterative bronchiolitis group
Number of subjects: 52
Study 7865532 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 2478779 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg/day)
Number of subjects: 0
Study 2478779 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg/day)
Number of subjects: 0
Study 2478779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 177210 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14)
Number of subjects: 65
Study 177210 — intervention group
Group type: COMPARATOR
Intervention: Previous combination of procarbazine, CCNU, and vincristine
Number of subjects: 65
Study 31704429 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath counting mindfulness training
Number of subjects: 192
Study 31704429 — intervention group
Group type: COMPARATOR
Intervention: Control group (popular science extract)
Number of subjects: 192
Study 31135850 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy
Number of subjects: 1056
Study 31135850 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 1056
Study 28625637 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2603618 + Pemetrexed + Cisplatin (LY+Pem+Cis)
Number of subjects: 62
Study 28625637 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed + Cisplatin (Pem+Cis)
Number of subjects: 62
Study 25924819 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg four times daily (q.i.d.)
Number of subjects: 30
Study 25924819 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg two times a day (b.i.d.)
Number of subjects: 30
Study 23949918 — intervention group
Group type: EXPERIMENTAL
Intervention: add-on extended release nicotinic acid/laropiprant (ER-NA/LRPT)
Number of subjects: 100
Study 23949918 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 100
Study 23949918 — intervention group
Group type: EXPERIMENTAL
Intervention: add-on fenofibrate
Number of subjects: 100
Study 21270789 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (B) 16 mg, n = 18
Number of subjects: 34
Study 21270789 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone (B/N) 16/4 mg, n = 16
Number of subjects: 34
Study 18650507 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of simvastatin daily
Number of subjects: 175
Study 18650507 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of simvastatin daily
Number of subjects: 175
Study 18650507 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified dosage)
Number of subjects: 175
Study 15861064 — intervention group
Group type: EXPERIMENTAL
Intervention: Blake drain
Number of subjects: 43
Study 12640070 — intervention group
Group type: EXPERIMENTAL
Intervention: Coeliac disease patients
Number of subjects: 49
Study 12640070 — intervention group
Group type: COMPARATOR
Intervention: Reflux disease patients
Number of subjects: 49
Study 10933183 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation (PBSCT)
Number of subjects: 74
Study 10933183 — intervention group
Group type: COMPARATOR
Intervention: Bone Marrow Transplantation (BM)
Number of subjects: 74
Study 8790926 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 65
Study 8790926 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide/triamterene
Number of subjects: 65
Study 1729864 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 104
Study 1729864 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil
Number of subjects: 104
Study 6429852 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg 2% nitroglycerin ointment (Plantorgan Co.)
Number of subjects: 44
Study 6429852 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg 2% nitroglycerin ointment (Pohl Boskamp Co.)
Number of subjects: 44
Study 6429852 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg nitroglycerin in the transdermal therapeutic system (Ciba Geigy)
Number of subjects: 44
Study 30910440 — intervention group
Group type: EXPERIMENTAL
Intervention: GSP301 (665 μg of olopatadine and 25 μg of mometasone)
Number of subjects: 1176
Study 30910440 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine (665 μg)
Number of subjects: 1176
Study 30910440 — intervention group
Group type: COMPARATOR
Intervention: Mometasone (25 μg)
Number of subjects: 1176
Study 30910440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1176
Study 29974521 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) 600 mg intravenous before graft reperfusion
Number of subjects: 40
Study 29974521 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 29974521 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) treatment
Number of subjects: 40
Study 27763846 — intervention group
Group type: EXPERIMENTAL
Intervention: NFTs with calories in large font
Number of subjects: 2008
Study 27763846 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic Light format with small font
Number of subjects: 2008
Study 27763846 — intervention group
Group type: EXPERIMENTAL
Intervention: Current, RDI and Traffic Light formats with large font
Number of subjects: 2008